Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725459 | SCV000700979 | likely pathogenic | not provided | 2015-10-28 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000596973 | SCV000792189 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-06-09 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000725459 | SCV003830931 | uncertain significance | not provided | 2019-03-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003736685 | SCV004551507 | likely pathogenic | Qualitative or quantitative defects of dysferlin | 2022-12-23 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DYSF protein function. ClinVar contains an entry for this variant (Variation ID: 284469). This missense change has been observed in individual(s) with DYSF-related conditions (PMID: 33250842). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 69 of the DYSF protein (p.Val69Gly). |